ICD-10 C34.02 is officially defined as "Malignant neoplasm of left main bronchus." code C34.02 is referenced in 10 tracked payer policy changes from Independence Blue Cross and Blue Cross & Blue Shield of Mississippi. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code C34.02 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Independence Blue Cross updated Medicare Advantage policy MA08.185a effective 11/02/2026 to align datopotamab deruxtecan-dlnk (Datroway®) coverage with FDA labeling and NCCN guidelines for non-small cell lung cancer and breast cancer. The policy adds specific ICD-10 diagnosis codes and clarifies HER2 testing requirements and clinical eligibility criteria for coverage.
Independence Blue Cross updated policy 08.02.41a for datopotamab deruxtecan-dlnk (Datroway®) effective 11/02/2026 to align with FDA labeling and NCCN guidelines. The policy adds 13 new ICD-10 diagnosis codes for lung and breast cancers and expands covered indications for the drug across invasive breast cancer, inflammatory breast cancer, unresectable or metastatic breast cancer, and non-small cell lung cancer, with HER2 testing requirements specified.
Independence Blue Cross Medicare Advantage policy MA08.183a expands coverage for Zenocutuzumab-zbco (Bizengri®) by removing a restrictive exclusion criterion for non-small cell lung cancer and adding 16 new ICD-10 diagnosis codes for pancreatic and lung cancer indications. The policy now covers the drug for NRG1 gene fusion-positive NSCLC and pancreatic adenocarcinoma under specified medical necessity criteria.
Independence Blue Cross expanded coverage for Zenocutuzumab-zbco (Bizengri®) by removing a parenthetical exclusion from non-small cell lung cancer criteria and adding 18 new ICD-10 diagnosis codes for pancreatic and lung malignancies effective June 1, 2026. Billing teams must update systems to recognize these newly covered diagnosis codes for claim submission.
Independence Blue Cross has reissued MA11.052f with minor updates to reflect the January 1, 2026 HCPCS/CPT code changes. CPT code 0600T narrative was revised and HCPCS code C9751 was terminated. The policy's coverage criteria for radiofrequency ablation, cryosurgical ablation, and microwave ablation of lung tumors remain substantively unchanged, but billing teams must update systems to reflect the terminated code and verify current code narratives.
Independence Blue Cross reissued Policy 11.00.16k on lung tumor ablation with minor updates effective 01/01/2026, including a CPT code narrative revision for code 0600T and termination of HCPCS code C9751. The policy maintains coverage for radiofrequency ablation, cryosurgical ablation, and microwave ablation under specified medical necessity criteria, while pulsed electric field ablation remains experimental/investigational.
Independence Blue Cross reissued Policy 11.00.16k on lung tumor ablation effective 01/01/2026 with updates to CPT code 0600T narrative and termination of HCPCS code C9751. The policy maintains coverage for radiofrequency ablation, cryosurgical ablation, and microwave ablation under specific medical necessity criteria, while designating pulsed electric field ablation as experimental/investigational.
Independence Blue Cross has published MA08.183a, a new Medicare Advantage coverage policy for zenocutuzumab-zbco (Bizengri®), establishing medical necessity criteria for NRG1 gene fusion–positive non-small cell lung cancer and pancreatic adenocarcinoma. Billing teams must verify patients meet specific criteria including prior systemic therapy progression, LVEF ≥50%, and applicable performance status before claims are submitted. This supersedes the previous MA08.183 version and becomes effective July 28, 2025.
Independence Blue Cross published a new policy (08.02.38a, effective 07/28/2025) establishing coverage criteria for zenocutuzumab-zbco (Bizengri®) for NRG1 gene fusion-positive non-small cell lung cancer and pancreatic adenocarcinoma. The policy requires specific clinical criteria including prior systemic therapy progression, LVEF ≥50%, and ECOG performance status documentation. All other uses are considered experimental/investigational and not covered.
Cryosurgical ablation may be considered medically necessary to treat localized renal cell carcinoma no more than 4 cm in size when kidney function preservation is necessary or the individual is not a surgical candidate, and to treat lung cancer in an individual with early-stage non-small-cell lung cancer who is a poor surgical candidate or who requires palliation of a central airway obstructing lesion. It is considered investigational for benign or malignant tumors of the breast, lung other than as defined above, pancreas, or bone, and for renal cell carcinoma in individuals who are surgical candidates. The policy history records a 09/12/2025 review with no changes.
Watch C34.02
Get one email when a payer policy names C34.02, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.